Mineralys Therapeutics (MLYS) Prepaid Assets (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Prepaid Assets of $6.4 million for Q1 2026, up 34.92% sequentially from $4.8 million in Q4 2025, and down 44.16% YoY from $11.5 million in Q1 2025.
Mineralys Therapeutics (MLYS) Prepaid Assets (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Prepaid Assets for 5 years, with the latest figure at $6.4 million in Q1 2026.
- Quarterly Prepaid Assets fell 44.16% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 44.16% YoY) and the FY2025 annual result came in at $4.8 million, down 33.68% from the prior year.
- Prepaid Assets climbed to $6.4 million in Q1 2026 per MLYS's latest filing, from $4.8 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $12.5 million in Q4 2023 and troughed at $2.7 million in Q4 2022.
- A 5-year average of $7.5 million and a median of $7.0 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets soared 364.12% in 2023, then slumped 64.45% in 2024.
- Over 5 years, Prepaid Assets stood at $2.7 million in 2022, then jumped by 364.12% to $12.5 million in 2023, then tumbled by 42.85% to $7.2 million in 2024, then sank by 33.68% to $4.8 million in 2025, then soared by 34.92% to $6.4 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $6.4 million, $4.8 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.39 Mn |
| Mar 31, 2026 | 6.41 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Sep 30, 2025 | 6.17 Mn |
| Jun 30, 2025 | 10.35 Mn |
| Mar 31, 2025 | 11.48 Mn |
| Dec 31, 2024 | 7.16 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Dec 31, 2023 | 12.54 Mn |
| Sep 30, 2023 | 11.61 Mn |
| Jun 30, 2023 | 8.39 Mn |
| Mar 31, 2023 | 4.64 Mn |
| Dec 31, 2022 | 2.70 Mn |